Capecitabine (Xeloda) in combination with oxaliplatin is an effective adjuvant treatment regimen for colon cancer when administered immediately after surgery, according to results from a phase III study announced recently by Roche and Genentech. The NO16968 (XELOXA) study showed that patients receiving the oral capecitabine/intravenous oxaliplatin combination (XELOX regimen) had longer disease-free survival than did patients treated with the all-intravenous chemotherapy regimen commonly used in these...